The U.S. Food and Drug Administration (FDA) has approved the nation’s first mRNA-based influenza vaccine, developed by Moderna. The agency authorized the shot for individuals aged 50 and older, specifically targeting two cohorts: those aged 50 to 64 and those 65 years and older.
Following the approval, Moderna announced plans to conduct a postmarket clinical trial to further confirm the vaccine's effectiveness. This regulatory milestone marks the introduction of mRNA technology into the seasonal flu vaccine market.
In-depth summary · AI, neutral
How the coverage differs
Same story, different emphasis — here's what each outlet chose to lead with.
WESH 2 (Orlando, US)Focuses on the core approval announcement for older adults.
The Hill (US)Highlights specific age cohorts and postmarket clinical trial requirements.
Newz